162 related articles for article (PubMed ID: 23504149)
21. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes.
Rojas A; Morales MA
Life Sci; 2004 Dec; 76(7):715-30. PubMed ID: 15581904
[TBL] [Abstract][Full Text] [Related]
22. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products.
Machado AP; Pinto RS; Moysés ZP; Nakandakare ER; Quintão EC; Passarelli M
Int J Biochem Cell Biol; 2006 Mar; 38(3):392-403. PubMed ID: 16288898
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
[TBL] [Abstract][Full Text] [Related]
24. The Mechanisms of Inhibition of Advanced Glycation End Products Formation through Polyphenols in Hyperglycemic Condition.
Khangholi S; Majid FA; Berwary NJ; Ahmad F; Aziz RB
Planta Med; 2016 Jan; 82(1-2):32-45. PubMed ID: 26550791
[TBL] [Abstract][Full Text] [Related]
25. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications.
Friedman EA
Diabetes Care; 1999 Mar; 22 Suppl 2():B65-71. PubMed ID: 10097902
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats.
Jeyabal PV; Kumar R; Gangula PR; Micci MA; Pasricha PJ
Neurogastroenterol Motil; 2008 Mar; 20(3):253-61. PubMed ID: 17971026
[TBL] [Abstract][Full Text] [Related]
27. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats.
Soulis T; Cooper ME; Sastra S; Thallas V; Panagiotopoulos S; Bjerrum OJ; Jerums G
Diabetologia; 1997 Oct; 40(10):1141-51. PubMed ID: 9349594
[TBL] [Abstract][Full Text] [Related]
28. Advanced glycation endproducts: what is their relevance to diabetic complications?
Ahmed N; Thornalley PJ
Diabetes Obes Metab; 2007 May; 9(3):233-45. PubMed ID: 17391149
[TBL] [Abstract][Full Text] [Related]
29. Effect of protocatechualdehyde on receptor for advanced glycation end products and TGF-beta1 expression in human lens epithelial cells cultured under diabetic conditions and on lens opacity in streptozotocin-diabetic rats.
Kim YS; Kim NH; Lee SW; Lee YM; Jang DS; Kim JS
Eur J Pharmacol; 2007 Aug; 569(3):171-9. PubMed ID: 17597607
[TBL] [Abstract][Full Text] [Related]
30. Atherosclerosis in chronic kidney disease: lessons learned from glycation in diabetes.
Mohar DS; Barseghian A; Haider N; Domanski M; Narula J
Med Clin North Am; 2012 Jan; 96(1):57-65. PubMed ID: 22391251
[TBL] [Abstract][Full Text] [Related]
31. The multifaceted therapeutic potential of benfotiamine.
Balakumar P; Rohilla A; Krishan P; Solairaj P; Thangathirupathi A
Pharmacol Res; 2010 Jun; 61(6):482-8. PubMed ID: 20188835
[TBL] [Abstract][Full Text] [Related]
32. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
[TBL] [Abstract][Full Text] [Related]
33. The pathological implications of protein glycation.
Brownlee M
Clin Invest Med; 1995 Aug; 18(4):275-81. PubMed ID: 8549013
[TBL] [Abstract][Full Text] [Related]
34. Substituted benzenediol Schiff bases as promising new anti-glycation agents.
Choudhary MI; Abbas G; Ali S; Shuja S; Khalid N; Khan KM; Atta-ur-Rahman ; Basha FZ
J Enzyme Inhib Med Chem; 2011 Feb; 26(1):98-103. PubMed ID: 20583858
[TBL] [Abstract][Full Text] [Related]
35. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.
Khalifah RG; Baynes JW; Hudson BG
Biochem Biophys Res Commun; 1999 Apr; 257(2):251-8. PubMed ID: 10198198
[TBL] [Abstract][Full Text] [Related]
36. Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
Engelen L; Stehouwer CD; Schalkwijk CG
Diabetes Obes Metab; 2013 Aug; 15(8):677-89. PubMed ID: 23279611
[TBL] [Abstract][Full Text] [Related]
37. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
38. Non-enzymatic glycation of proteins: a cause for complications in diabetes.
Nawale RB; Mourya VK; Bhise SB
Indian J Biochem Biophys; 2006 Dec; 43(6):337-44. PubMed ID: 17285797
[TBL] [Abstract][Full Text] [Related]
39. [Glycation and protein crosslinking in the diabetes and ageing pathogenesis].
Cárdenas-León M; Díaz-Díaz E; Argüelles-Medina R; Sánchez-Canales P; Díaz-Sánchez V; Larrea F
Rev Invest Clin; 2009; 61(6):505-20. PubMed ID: 20184132
[TBL] [Abstract][Full Text] [Related]
40. Antiglycation therapy: Discovery of promising antiglycation agents for the management of diabetic complications.
Abbas G; Al-Harrasi AS; Hussain H; Hussain J; Rashid R; Choudhary MI
Pharm Biol; 2016; 54(2):198-206. PubMed ID: 25853955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
